Selective inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp). Increases the sensitivity of MRP1-overexpressing tumor cells (MCF7/VP) to doxorubicin
(Cat. No. 2252), vincristine
(Cat. No. 1257) and etoposide
(Cat. No. 1226) by 3.8-, 14.6- and 11.6-fold respectively. Increases the efficacy of vincristine and etoposide in murine models of neuroblastoma in vivo
. Does not sensitize MRP2, MRP3, MRP4 or MRP5 transporters to known substrates.
Soluble to 25 mM in DMSO
Store at RT
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.
Burkhart et al.
Cancer Res., 2009;69:6573